Clinical Trials Logo

Clinical Trial Summary

The goal of the clinical trial is to investigate adherence to, and effects of, the Bluedrop Monitoring System (BMS) in high-risk patients with at least one previous diabetic foot ulcer (DFU). The BMS is a remote thermovisual monitoring system, which allows the condition of the soles of the feet to be remotely monitored for thermal and visual signs of inflammation, both of which may signal the onset of certain conditions, such as diabetic foot ulcers. It is comprised of the Delta Foot Scanner (DFS) device and its accompanying Sentinel Review Interface (SRI) software. The Covid-19 pandemic has driven the need for remote patient care where possible. Although this is challenging for people with foot ulcers, prevention is the key. Remote thermovisual monitoring might help reduce recurrent foot ulcers and therefore the number of necessary hospital visits which always puts the patient at increased risk of Covid infection.


Clinical Trial Description

Despite the introduction of preventative foot care guidelines DFUs have a high re-ulceration rate. In the first 12 months following healing, 30-50% will develop a subsequent DFU and by year 5 this rate increases to 70%. Temperature monitoring has been proposed as a way to reduce this re-ulceration rate but has not been widely adopted. Based on the existing evidence groups such as the International Working Group on the Diabetic Foot (IWGDF) have recommended temperature monitoring for the prevention of recurrent foot ulcers. Despite these recommendations the technique has not been widely adopted. This is likely due to a number of factors, but NICE, in their guidance document for the prevention and management of foot ulcers (NG19) states: "While temperature foot monitoring was found to be the only effective form of augmented self-examination, the intervention tool was felt to be quite difficult to use and required a strongly motivated population to actually perform consistently and fill out the required log books". Bluedrop Medical have developed a product which leverages the existing evidence on temperature monitoring but builds it into a device which also includes the ability to take photographic images, is easy to use, and can integrate well with the healthcare system. The goal of the clinical trial is to demonstrate that patients will use the device consistently over the course of the study. It will also be used to determine the clinician reported utility of thermovisual data to conduct a remote assessment or remote intervention. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05039645
Study type Interventional
Source Bluedrop Medical Limited
Contact Caroline Abbott, PhD
Phone 07801352918
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date September 2021
Completion date February 2022

See also
  Status Clinical Trial Phase
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Recruiting NCT03865394 - Treatment of Chronic Wounds in Diabetic Foot Syndrome With Autologous Adipose Derived Mesenchymal Stem Cells Phase 1/Phase 2
Not yet recruiting NCT03640988 - The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs N/A
Recruiting NCT05046158 - Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care N/A
Recruiting NCT04323462 - Intensive Glycemic Control For Diabetic Foot Ulcer Healing Phase 4
Not yet recruiting NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Not yet recruiting NCT05007301 - Geko™ Cross Therapy Registry - Wound
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A
Not yet recruiting NCT05009602 - Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Not yet recruiting NCT04709419 - Celliant Socks to Increase Tissue Oxygenation and Complete Wound Closure in Diabetic Foot Wounds N/A
Not yet recruiting NCT04939038 - Timing of Revascularization in Patients With Diabetic Foot Ulcer and Non-critical Peripheral Artery Disease N/A